Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

Leukemia volume 22, pages 730–739 (2008)Cite this article

Abstract

In pediatric acute lymphoblastic leukemia (ALL), overexpression of murine double minute 2 (MDM2) protein by leukemic cells is typically associated with a wild-type (wt)-p53 phenotype and chemoresistance. A recently developed small-molecule antagonist of MDM2, nutlin-3, inhibits the MDM2–p53 interaction, resulting in induction of p53 activity and apoptosis. In this study, we evaluated the cytotoxic effect of nutlin-3 on ALL cells with different p53 status and MDM2 expression, using 18 cell lines and 30 primary leukemia samples. We found that both ALL cell lines and primary ALL samples with wt-p53 are sensitive to nutlin-3. No cytotoxic effect of nutlin-3 was detected in ALL cells with either p53-mutant or -null phenotype. In wt-p53 ALL cells, there was a significant positive correlation between MDM2 expression levels and sensitivity to nutlin-3. Nutlin-3-induced cell death was mediated by p53-induced activation of proapoptotic proteins and by p53-induced repression of the anti-apoptotic protein survivin. As p53 function is inhibited by MDM2 in chemoresistant, MDM2-overexpressing ALL cells, potent killing of these cells by nutlin-3 suggests that this agent may be a novel therapeutic for refractory ALL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Vousden KH, Lu X . Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604.

    Article  CAS  PubMed  Google Scholar 

  2. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P . The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607–614.

    Article  CAS  PubMed  Google Scholar 

  3. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H et al. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1156.

    CAS  PubMed  Google Scholar 

  4. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M . Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994; 83: 2922–2930.

    CAS  PubMed  Google Scholar 

  5. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M et al. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42–46.

    CAS  PubMed  Google Scholar 

  6. Wolf D, Rotter V . Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82: 790–794.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Soudon J, Caron de Fromentel C, Bernard O, Larsen CJ . Inactivation of the p53 gene expression by a splice donor site mutation in a human T-cell leukemia cell line. Leukemia 1991; 5: 917–920.

    CAS  PubMed  Google Scholar 

  8. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M . The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617–2623.

    CAS  PubMed  Google Scholar 

  9. Zhou M, Yeager AM, Smith SD, Findley HW . Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85: 1608–1614.

    CAS  PubMed  Google Scholar 

  10. Gustafsson B, Stal O, Gustafsson B . Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15: 519–526.

    Article  CAS  PubMed  Google Scholar 

  11. Zhou M, Gu L, Abshire T, Homans A, Yeager AM, Findley HW . Incidence and prognostic significance of MDM2 oncoprotein overexpresion in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 61–67.

    Article  CAS  PubMed  Google Scholar 

  12. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155–1161.

    CAS  PubMed  Google Scholar 

  13. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15: 1158–1162.

    Article  CAS  PubMed  Google Scholar 

  14. Gustafsson B, Christenson B, Hjalmar V, Winiarski J . Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 2000; 34: 117–124.

    Article  CAS  PubMed  Google Scholar 

  15. Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J . MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 2001; 18: 497–508.

    Article  CAS  PubMed  Google Scholar 

  16. Momand J, Jung D, Wilczynski S, Niland J . The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453–3459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Momand J, Zambetti GP, Olson D, George D, Levine AJ . The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245.

    Article  CAS  PubMed  Google Scholar 

  18. Honda R, Tanaka H, Yasuda H . Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25–27.

    Article  CAS  PubMed  Google Scholar 

  19. Mayo LD, Donner DB . A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598–11603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhou M, Gu L, Findley HW, Jiang R, Woods WG . PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63: 6357–6362.

    CAS  PubMed  Google Scholar 

  21. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.

    Article  CAS  PubMed  Google Scholar 

  22. Logan IR, McNeill HV, Cook S, Lu X, Lunec J, Robson CN . Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate 2007; 67: 900–906.

    Article  CAS  PubMed  Google Scholar 

  23. VanderBorght A, Valckx A, Van Dun J, Grand-Perret T, De Schepper S, Vialard J et al. Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene 2006; 25: 6672–6677.

    Article  CAS  PubMed  Google Scholar 

  24. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006; 66: 9646–9655.

    Article  CAS  PubMed  Google Scholar 

  25. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007; 13: 3380–3387.

    Article  CAS  PubMed  Google Scholar 

  26. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609–3617.

    Article  PubMed  Google Scholar 

  27. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150–3159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Lasio MG, Gonelli A et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122–4129.

    Article  CAS  PubMed  Google Scholar 

  29. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109–4114.

    Article  CAS  PubMed  Google Scholar 

  30. Pui CH, Crist WM . High risk lymphoblastic leukemia in children: prognostic factors and management. Blood Rev 1987; 1: 25–33.

    Article  CAS  PubMed  Google Scholar 

  31. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247–3257.

    Article  CAS  PubMed  Google Scholar 

  32. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW . DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303: 124–131.

    Article  CAS  PubMed  Google Scholar 

  33. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613–2622.

    Article  CAS  PubMed  Google Scholar 

  34. Pui CH, Evans WE . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.

    Article  CAS  PubMed  Google Scholar 

  35. Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM et al. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 2003; 278: 9747–9753.

    Article  CAS  PubMed  Google Scholar 

  36. Arai K, Matsumoto Y, Nagashima Y, Yagasaki K . Regulation of class II beta-tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to vinca alkaloid. Mol Cancer Res 2006; 4: 247–255.

    Article  CAS  PubMed  Google Scholar 

  37. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 1999; 23: 871–880.

    Article  CAS  PubMed  Google Scholar 

  38. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883–10892.

    Article  CAS  PubMed  Google Scholar 

  39. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723–2729.

    CAS  PubMed  Google Scholar 

  40. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R . In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959–2965.

    CAS  PubMed  Google Scholar 

  41. Srinivas G, Kusumakumary P, Joseph T, Pillai MR . In vitro drug sensitivity and apoptosis induction in newly diagnosed pediatric acute lymphoblastic leukemia: correlation with overall survival. Pediatr Hematol Oncol 2004; 21: 465–473.

    Article  CAS  PubMed  Google Scholar 

  42. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005; 24: 7542–7551.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Leukemia and Lymphoma Society (6249-05 and 6033-08), CURE Childhood Cancer and Hope Street Kids (HSK).

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

    L Gu, N Zhu, H W Findley & M Zhou

Authors
  1. L Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H W Findley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gu, L., Zhu, N., Findley, H. et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 22, 730–739 (2008). https://doi.org/10.1038/leu.2008.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.11

Keywords

This article is cited by

Search

Advanced search

Quick links